摘要
目的探讨ARID1a基因在子宫内膜增生病变组织中的表达及与性激素受体表达的相关性,为子宫内膜增生症的防治提供新的思路。方法采用免疫组化SP(streptavidin peroxidase-biotin,SP)法,检测132例子宫内膜病变组织(单纯性增生40例,复杂性增生40例,不典型增生52例)及28例增殖期子宫内膜组织中ARID1a、雌激素受体(ER)、孕激素受体(PR)、雄激素受体(AR)的阳性表达率。结果 (1)在子宫内膜组织中,普遍存在ER、PR、AR受体的表达。ER、PR阳性表达率各组间比较,差异无统计学意义(P>0.05);AR在不典型增生症组中表达率最低,与其余各组间比较,差异有统计学意义(P<0.05),增殖期内膜组、单纯性增生组、复杂性增生组各组间比较,差异无统计学意义(P>0.05)。(2)ARID1a基因在子宫内膜腺上皮和间质细胞核中普遍表达,在不典型子宫内膜组织中表达丢失率为19.2%,与其余各组间比较,差异有统计学意义(P<0.05);增殖期内膜组、单纯性增生组、复杂性增生组间,差异无统计学意义(P>0.05)。(3)ARID1a基因的表达与ER、PR、AR之间无相关性。结论雄激素及其受体与子宫内膜病变风险显著相关,ARID1a基因突变和表达缺失是子宫内膜增生恶变中的一个早期事件;对于雄激素受体阳性患者采用联合降低雄激素的治疗,将有可能成为子宫内膜增生症患者治疗的新思路。
Objective To investigate the expression of ARID1 a,in endometrial hyperplasia and its correlation wits sex hormone receptors.Methods Expressions of ARID1 a,ER,PR and AR were detected with immunohistochemistry technic（streptavidin peroxidase-biotin,SP）in 160 cases including 28 of proliferative endometrium,40 of Simple endometrial hyperplasia,40 of Complex endometrial hyperplasia,52 of atypical proliferation.Results（1）The expression of ER,PR and AR receptors exist widely in the proliferative phase endometrium,atypical endometrial tissue,atypical endometrial hyperplasia.The positive expression rate of ER between these groups is not statistically significant;the positive expression rate of PR shows a tendency of decrease with the lowest expression rate appearing in atypical endometrial hyperplasia tissues;differences in the positive expression rate of AR in proliferative endometrium and all typical endometrial tissues had no significant statistical significance with the lowest expression rate existing in the group of atypical hyperplasia,the difference is statistically significant（P=0.018）.（2）ARID1a gene has expression both in endometrial glandular epithelial and stromal cell nucleus,and the expression loss rate is 19.2% in atypical endometrial tissues.Compared with other groups, the atypical hyperplasia group has a significant statistical difference（P=0.004）.（3）There is no correlation between ARID1 a gene and ER,PR,AR.Conclusion Androgen and its receptor are significantly associated with the risk of endometrial hyperplasia.ARID1 a gene mutation and expression of endometrial hyperplasia canceration in an early event;The treatment of androgen receptor positive patients with combined reduction of androgen will likely become a new idea for the treatment of endometrial hyperplasia.
出处
《实用妇科内分泌电子杂志》
2017年第1期78-80,82,共4页
Electronic Journal of Practical Gynecological Endocrinology
